News
- Bioprinting Laboratories Inc. awarded $285,000 NIH/NIEHS SBIR Phase I grant for developing genetically engineered human liver organoids to assess hepatotoxicity among poor and ultrafast metabolizers. - 8/1/23
- Bioprinting Laboratories Inc. has been relocated to Farmers Branch, Texas. - 8/1/23
- Bioprinting Laboratories Inc. awarded $84,000 grant from Medical & Bio Decision (MBD) in South Korea for cancer research. - 6/1/23
- Dr. Lee received “Third Place Award” in Business Plan Competition at TERMIS-AM 2023 Conference. - 4/12/23
- Bioprinting Laboratories Inc. received $1 million angel investment for commercialization of pillar/perfusion plates for human organoid culture and analysis. - 2/14/23
- Dr. Lee is selected as a Cohort of BioNTX Tech Transfer Office Showcase and Pitch Competition at 2022 iC3 Life Science Summit. - 9/23/22
- Bioprinting Laboratories Inc. awarded $84,000 grant from Medical & Bio Decision (MBD) in South Korea for cancer research. - 4/12/22
- Bioprinting Laboratories Inc. awarded $50,000 grant from Colgate-Palmolive for antimicrobial research. - 9/1/21
- Bioprinting Laboratories Inc. has been relocated to Denton, Texas. - 8/16/21
- Dr. Lee and his research collaborators at Cincinnati Children’s Hospital Medical Center and University of Illinois at Chicago awarded $5.35 million NIH/NIDDK UH3 grant for modeling type II diabetes on pillar/perfusion plate platforms. - 8/6/20
- Bioprinting Laboratories Inc. awarded $838,000 NIH/NCATS SBIR Phase II grant for commercializing pillar/perfusion plate platforms for robust organoid culture and analysis. - 7/16/20
- Dr. Lee awarded $150,000 TVSF Phase II grant for his startup company, Bioprinting Laboratories Inc. - 5/1/19
- Dr. Lee awarded $80,000 grant from Colgate-Palmolive for antimicrobial research. - 2/28/19
- Dr. Lee and his team received $1.69 million grant to enhance disease modeling. - 10/16/18
- Dr. Lee awarded $100,000 TeCK Fund grant for commercialization of microarray 3D bioprinting technology. - 1/23/18
- Dr. Lee established Bioprinting Laboratories Inc. to commercialize “microarray 3D bioprinting” technology. - 11/1/17
- Dr. Lee is selected as one of 5 finalists in Transform Tox Testing Challenge (Stage 2) supported by US EPA and NIH. - 10/27/17
- Dr. Lee's team is selected as 2017 Cohort of I-Corps@Ohio program. In this program, Dr. Lee and his team members will develop business strategy and market analysis for commercializing a 384-pillar plate with sidewalls for miniaturized human tissue regeneration. - 3/20/17